| abstract |
The present application relates to a method for detecting a MG 53-related disease or predicting the risk of a MG 53-related disease, the method comprising the steps of: a. obtaining a sample to be detected; detecting extracellular free MG53 in the test sample. The application also relates to a method for reducing or inhibiting extracellular free MG53 activity in a guest, the method comprising administering to a guest in need thereof an effective amount of an MG53 inhibitor. In addition, the present application relates to an MG53 antibody or antigen-binding fragment thereof, nucleic acids encoding the antibody or antigen-binding fragment thereof, cloning or expression vectors comprising the nucleic acids, host cells comprising the cloning or expression vectors, and pharmaceutical compositions comprising each of the foregoing. Furthermore, the application also relates to a detection reagent for detecting the extracellular free MG53 and application thereof, and application of the MG53 inhibitor in preparing a medicament for reducing or inhibiting the extracellular free MG53 in the object. |